Neuland Laboratories

    NEULANDLAB
    Pharma
    ₹21,455.00
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹27,527 Cr

    P/E
    60.83
    Day range
    ₹21,060.00 – ₹21,661.00
    52-week range
    ₹11,500.00 – ₹24,225.00
    Volume
    45,676
    Open
    ₹21,200.00
    Prev close
    ₹21,445.00

    Latest results · Q2 FY27(consolidated)Revenue ₹450 Cr-12.6%Profit ₹52 Cr-46.7%Margin 11.5%YoY vs the same quarter last year

    1 red flag to read up on

    • medium

      Promoter pledge went up

      2.32% of promoter shares pledged, up from 2.29% · 30 Sept 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Composite 51 / 100

    Factor percentiles

    Value20
    Quality61
    Momentum69
    Low volatility52

    Derived metrics

    Earn. yield
    1.6%
    Graham no.
    ₹3,526.75
    vs Graham
    -83.6%
    ROE ÷ P/B
    1.6%
    12-1 mom.
    +8.6%
    Return / vol
    0.50
    Magic Formula
    #338
    Piotroski
    2/6
    FCF yield
    -0.2%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Neuland LaboratoriesNEULANDLAB₹27,527 Cr60.8313.6821.4%26.0%22.0%0.17-12.5%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 8d ago

    Headlines about Neuland Laboratories from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    61.4
    Price / Book
    13.56
    ROE (FY26)
    21.4%
    ROCE (latest year)
    26%
    Dividend yield
    0.16%

    Moving averages (NSE)

    20-day
    ₹19,961
    Price above
    50-day
    ₹21,088.6
    Price above
    200-day
    ₹17,782.66
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +19.3%
    Profit 3Y CAGR
    +30.4%
    Revenue YoY (Sep 2026)
    -12.5%
    Profit YoY (Sep 2026)
    -46.4%
    Operating margin
    22.0%
    Net margin
    11.6%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr200 Cr400 Cr600 Cr800 Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%20%40%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • Public
    • FII
    • DII
    • Government

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-600 Cr-400 Cr-200 Cr0 Cr200 Cr400 Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%10%20%30%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr1K Cr2K Cr3K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY18FY19FY20FY21FY22FY23FY24FY25FY26FY27₹0₹10₹20₹30₹40

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales393385440311398328293514440776642450
    YoY Sales growth—-5—-26—-15-33————-13
    Expenses272278316249311277258359363469419352
    Operating Profit121107123628751341567730722398
    OPM %31%28%28%20%22%16%12%30%18%40%35%22%
    Other Income252546078281288
    Interest443122557777
    Depreciation151616161617202324252729
    Profit before tax104921304912839181295428719869
    Tax %22%27%25%34%20%29%21%25%26%26%25%25%
    Net Profit816898331022814974121314852
    EPS in Rs₹63.44₹52.66₹76.28₹25.60₹79.18₹21.68₹10.83₹75.49₹31.62₹165.76₹115.10₹40.24

    From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days98

    +13 days since Mar 2021

    Inventory Days245

    +40 days since Mar 2021

    Days Payable129

    +3 days since Mar 2021

    Cash Conversion Cycle214

    +50 days since Mar 2021

    Working Capital Days75

    +15 days since Mar 2021

    Strengths, risks & growth

    Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. [1]

    Strengths

    • Company is expected to give good quarter
    • Company has delivered good profit growth of 38.5% CAGR over last 5 years

    Risks

    • Stock is trading at 13.7 times its book value
    • Promoter holding has decreased over last quarter: -0.36%

    Compounded Sales Growth

    10 Years
    +15%
    5 Years
    +17%
    3 Years
    +19%
    TTM
    +50%

    Compounded Profit Growth

    10 Years
    +29%
    5 Years
    +39%
    3 Years
    +30%
    TTM
    +131%

    Stock Price CAGR

    10 Years
    +36%
    5 Years
    +67%
    3 Years
    +59%
    1 Year
    +25%

    Return on Equity

    10 Years
    +14%
    5 Years
    +18%
    3 Years
    +20%
    Last Year
    +21%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter32.63%32.63%32.62%32.26%-0.36 pp
    FII20.90%20.46%21.08%21.93%+0.85 pp
    DII14.72%15.84%16.52%16.25%-0.27 pp
    Government0.00%0.00%0.00%0.00%0.00 pp
    Public31.76%31.08%29.79%29.55%-0.24 pp

    Filed with NSE for Sept 2026: promoters 32.26%, public 67.74%

    Analysts & fund holdings

    100%
    100% recommend buy
    4 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E60.8 vs 45.2
    Sector P/B6.05
    Beta1.21

    Who holds the shares, quarter by quarter

    Mutual funds 12.45% (-0.21 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters32.3%
    • Foreign institutions21.9%
    • Mutual funds12.4%
    • Insurance1.4%
    • Other domestic institutions2.5%
    • Retail15.7%
    • Others13.8%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    HDFC Flexi Cap Fund2.27%0.58%+0.31 pp
    HSBC Small Cap Fund1.15%1.84%+0.11 pp
    ICICI Pru Flexi Cap Fund1.05%1.14%-0.64 pp
    Mahindra Manulife Multi Cap Fund0.68%2.56%-0.98 pp
    Mahindra Manulife Small Cap Fund0.43%2.32%-1.55 pp

    Scorecard

    Performance
    High
    Valuation
    High
    Growth
    Avg
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    37.2%
    Downside volatility
    30.5%
    Worst 5% of days
    3.4%
    Average of that tail
    4.1%
    Max drawdown (1Y)
    36.2%
    Below its peak
    10.6%

    Against the market

    Beta vs Nifty 50
    0.82
    Correlation
    0.30
    Relative strength (3M)
    -13.2%
    ATR (14)
    3.6%

    Return

    Return 1M
    +9.0%
    Return 3M
    -9.3%
    Return 6M
    +31.4%
    Return 1Y
    +18.5%
    vs 200-day average
    +20.7%

    Momentum

    RSI (14)
    62.6
    MACD histogram
    309.19
    Stochastic %K
    91.8
    ADX (14)
    33.6
    +DI / −DI
    21.9 / 13.3
    Money flow index
    52.6

    Participation

    Delivery (20d avg)
    49.5%
    vs its 60-day baseline
    +0.9 pts
    Volume vs 20-day
    -0.5σ
    Close vs day's VWAP
    +0.4%
    52-week position
    80 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    2 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — failed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — failed
    • Current ratio improving — passed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — failed
    • Asset turnover improving — failed
    Free cash flow
    -₹50 Cr
    FCF yield
    -0.2%
    Cash conversion
    0.95
    Accruals ratio
    0.006
    Net debt
    ₹289 Cr
    Net debt / equity
    0.14
    EV / sales
    12.06
    Capex intensity
    19.6%
    Revenue CAGR
    23.3%
    Profit CAGR
    51.0%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    No market trades
    3 buys · ₹0
    3 sells · ₹0
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    Davuluri Rohini Niveditha Rao
    Promoter Group · Gift
    Sell10,000₹028 Sept 2026
    Davuluri Saharsh Rao
    Promoter and Director · Gift
    Buy10,000₹028 Sept 2026
    Davuluri Saharsh Rao
    Promoters · Pledge Creation
    Pledge96,000₹116 Cr26 Mar 2026
    Davuluri Saharsh Rao
    Promoters · Gift
    Sell12,500₹05 Mar 2026
    Deepthi Davuluri
    Promoter Group · Gift
    Buy12,500₹05 Mar 2026
    Mr. Gannabathula Venkata Krishna Rama Rao
    Promoters · Gift
    Sell6,000₹017 Dec 2025
    Ms. Kamala Tayaramma Kommula
    Promoter Group
    Buy6,000₹017 Dec 2025

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    • dividend
      ₹34.00

      Dividend - Rs 34 Per Share

      24 Jul 2026
      ex-date
    • dividend
      ₹12.00

      Dividend - Rs 12 Per Share

      18 Jul 2025
      ex-date
    • dividend
      ₹14.00

      Annual General Meeting/Dividend - Rs 14 Per Share

      12 Jul 2024
      ex-date
    • dividend
      ₹10.00

      Annual General Meeting/Dividend - Rs 10 Per Share

      11 Jul 2023
      ex-date
    • dividend
      ₹5.00

      Annual General Meeting/Dividend - Rs 5 Per Share

      14 Jul 2022
      ex-date
    • dividend
      ₹3.00

      Annual General Meeting/Dividend - Rs 3 Per Share

      29 Jun 2021
      ex-date
    • dividend
      ₹2.00

      Interim Dividend - Rs 2 Per Share

      10 Nov 2020
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      2 Jul 2020
      ex-date
    • dividend
      ₹2.00

      Interim Dividend - Rs 2 Per Share

      18 Feb 2020
      ex-date
    • dividend
      ₹1.20

      Annual General Meeting/Dividend - Rs 1.20 Per Share

      27 Jun 2019
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      3 Aug 2018
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting (Date Revised)

      21 Dec 2017
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting/ Dividend - Rs 2/- Per Share

      4 Aug 2016
      ex-date
    • dividend
      ₹1.50

      Annual General Meeting/Dividend Rs 1.50 Per Share

      6 Aug 2015
      ex-date
    • rights
      Not available — not reported in this filing

      Rights Issue 4 : 25 @ Premium Rs 194/- Per Equity Share

      13 Aug 2014
      ex-date
    • dividend
      ₹1.50

      Annual General Meeting/Final Dividend Rs.1.50 Per Share And Special Dividend Rs.1.50 Per Share

      16 Jun 2014
      ex-date
    • dividend
      ₹1.20

      Annual General Meeting And Dividend Rs.1.20 Per Share

      24 Jul 2013
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      3 Aug 2012
      ex-date
    • rights
      Not available — not reported in this filing

      Rights 5:12 @ Premium Rs.35/- Per Share

      21 Mar 2012
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      29 Jul 2011
      ex-date

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Copy of Newspaper Publication

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2026

    Neuland Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve the unaudited Financial ....

    Company Update
    Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015

    We refer to our letter dated August 14, 2026 regarding the US FDA inspection conducted at our Unit 3 manufacturing facility and we would like to inform that the US FDA has issued an EIR ....

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018

    Insider Trading / SAST
    Closure of Trading Window
    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation about Schedule of Analyst / Institutional Investor Meeting on September 23 - 25, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Press Release

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation about Schedule of Analyst / Institutional Investor Meeting on September 15, 2026 and September 17, 2026

    Company Update
    Disclosure Under Regulation 30 Of SEBI Listing Regulations

    Disclosure under Regulation 30 of SEBI Listing Regulations

    Company UpdatePrice-sensitive
    Announcement under Regulation 30 (LODR)-Credit Rating

    Announcement under Regulation 30 (LODR) - Credit Rating

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Copy of Newspaper Publication

    Insider Trading / SAST
    Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Malabar India Fund Ltd

    Company Update
    Intimation Regarding Completion Of US FDA Inspection

    Intimation regarding completion of US FDA Inspection

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Transcript of the Earnings Call conducted on August 5, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation about Schedule of Analyst / Institutional Investor Meeting on August 12, 2026

    Filed with BSE (scrip 524558); the last 45 days. Documents open at bseindia.com.

    SEBI filings & orders

    From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.

    Buybacks, open offers & rights issues

    Regulatory orders

    • Order

      Exemption Order under Regulation 11 of SEBI (SAST) Regulations, 2011 in the matter of Neuland Laboratories Limited

      3 Jan 2025
      Read on SEBI

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 3 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Neuland Laboratories: common questions

    Answered from the figures on this page.

    Neuland Laboratories last traded at ₹21,455.00 (NSE, as of 18 Nov 2026). The last session moved it up 0.05%.

    Neuland Laboratories is valued at about ₹27,527 crore (NSE, as of 18 Nov 2026).

    Neuland Laboratories trades at a price-to-earnings ratio of 60.83 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Neuland Laboratories has traded between ₹11,500.00 and ₹24,225.00 over the past 52 weeks, to 18 Nov 2026. It is currently 78% of the way up that range.

    Neuland Laboratories (NEULANDLAB) is classified under Pharma on this site's screener.